Are you Dr. Arrowsmith?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 107 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
605 Glenwood Avenue
Suite 200
Chattanooga, TN 37404Phone+1 423-698-1844Fax+1 423-624-2226
Summary
- Dr. Edward Arrowsmith, MD is an oncologist in Chattanooga, Tennessee. He is currently licensed to practice medicine in Tennessee and Georgia. He is affiliated with CHI Memorial and Parkridge Medical Center.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1999- Vanderbilt University Medical CenterResidency, Internal Medicine, 1992 - 1995
Vanderbilt University School of MedicineClass of 1992
Certifications & Licensure
TN State Medical License 1995 - 2026
GA State Medical License 2000 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012
Clinical Trials
- Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary Start of enrollment: 2009 Feb 01
- A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Start of enrollment: 2015 Jul 29
- Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours Start of enrollment: 2019 Feb 12
Publications & Presentations
PubMed
- Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.Toni K Choueiri, Jaime R Merchan, Robert Figlin, David F McDermott, Edward Arrowsmith
The Lancet. Oncology. 2025-01-01 - 1 citationsClinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.Thomas Stricker, Neha Jain, Esprit Ma, Elaine Yu, Rongrong Wang
The Oncologist. 2024-06-03 - 3 citationsA phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.Gerald S Falchook, James Reeves, Sunil Gandhi, David R Spigel, Edward Arrowsmith
Cancer Immunology, Immunotherapy. 2024-03-02
